| Literature DB >> 35542836 |
Feng-Lei Li1, Jiang-Ping Yu1, Wei Ding1, Mian-Mian Sun1, Yun-Gang He1, Xing-Liang Zhu1, Shi-Ling Liu2, Xiao-Xin Shi1.
Abstract
N-Octyl-β-valienamine (NOV) 1 and N-octyl-4-epi-β-valienamine (NOEV) 2 are potent chemical chaperone drug candidates for the therapy of lysosomal storage disorders. Novel stereoselective syntheses of NOV 1 and NOEV 2 starting from naturally abundant (-)-shikimic acid are described in this article. The common key intermediate compound 5 was first synthesized from readily available (-)-shikimic acid via 9 steps in 50% yield. Compound 5 was then converted to NOV 1via 5 steps in 61% yield, and it was also converted to NOEV 2via 8 steps in 38% yield. In summary, NOV 1 was synthesized via 14 steps in 31% overall yield; and NOEV 2 was synthesized via 17 steps in 19% overall yield. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35542836 PMCID: PMC9076550 DOI: 10.1039/c9ra09235h
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1The structures of some related compounds.
Scheme 1The stereoselective synthesis of N-octyl-β-valienamine (NOV) 1 starting from (−)-shikimic acid.
Scheme 2The stereoselective synthesis of N-octyl-4-epi-β-valienamine (NOEV) 2 starting from (−)-shikimic acid.